Faster-acting insulin aspart: Earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

Diabetes, Obesity and Metabolism

Volumn 17, Issue 7, 2015, Pages 682-688

  Heise, Tim ^a   Hovelmann U ^a   Brondsted L ^b   Adrian, C L ^b   Nosek, L ^a   Haahr, H ^b  

^a Profil   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Faster acting insulin aspart; Pharmacodynamics; Pharmacokinetics; Postprandial glucose; Type 1 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN ASPART; NEUTRAL INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENCY; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TIME;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84931956619     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12468     Document Type: Article

References (27)

1. Woerle HJ, Neumann C, Zschau S etal. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007; 77: 280-285.
2. International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract 2014; 103: 256-268.
3. Nesher R, Cerasi E. Modeling phasic insulin release: immediate and time-dependent effects of glucose. Diabetes 2002; 51(Suppl. 1): S53-59.
4. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988; 37: 736-744.
5. Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev 2001; 17: 164-174.
6. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989; 257: E241-246.
7. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol 2012; 6: 728-742.
8. Brunner GA, Hirschberger S, Sendlhofer G etal. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000; 17: 371-375.
9. Heinemann L, Heise T, Wahl LC etal. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996; 13: 625-629.
10. Heise T. Getting closer to physiologic insulin secretion. Clin Ther 2007; 29(Suppl. D): S161-165.
11. Cobry E, McFann K, Messer L etal. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther 2010; 12: 173-177.
12. Luijf YM, van Bon AC, Hoekstra JB, Devries JH. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010; 33: 2152-2155.
13. Howey DC, Bowsher RR, Brunelle RL etal. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995; 58: 459-469.
14. Lampe J, Penoyer DA, Hadesty S etal. Timing is everything: results to an observational study of mealtime insulin practices. Clin Nurse Spec 2014; 28: 161-167.
15. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999; 43: 137-142.
16. Food and Drug Administration. Inactive ingredient search for approved drug products. 2013. Available from URL: http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm. Accessed April 2015.
17. Heise T, Hermanski L, Nosek L etal. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
18. Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H. Distinct prandial and basal glucose lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes. Diabetes Ther 2014; 5: 255-265.
19. Workgroup on Hypoglycemia ADA. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
20. Heinemann L, Weyer C, Rave K etal. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Exp Clin Endocrinol Diabetes 1997; 105: 140-144.
21. Bruttomesso D, Pianta A, Mari A etal. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105.
22. Rossetti P, Porcellati F, Fanelli CG etal. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 2008; 114: 3-10.
23. Cengiz E. Undeniable need for ultrafast-acting insulin: the pediatric perspective. J Diabetes Sci Technol 2012; 6: 797-801.
24. Shah VN, Shoskes A, Tawfik B, Garg SK. Closed-loop system in the management of diabetes: past, present, and future. Diabetes Technol Ther 2014; 16: 477-490.
25. Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J Diabetes Sci Technol 2012; 6: 764-772.
26. Krasner A, Pohl R, Simms P etal. A review of a family of ultra-rapid-acting insulins: formulation development. J Diabetes Sci Technol 2012; 6: 786-796.
27. Heise T, Haahr H, Jensen L etal. Faster-acting insulin aspart improves postprandial glycemia vs insulin aspart in patients with type 1 diabetes mellitus (T1DM). Diabetes 2014; 63(Suppl. 1): A34 (129-OR).